Market Overview

Merck, GE Healthcare Announce Collaboration on Use of Imaging Biomarkers for Investigational BACE Inhibitor Program

Related MRK
MITICURE for house Dust Mite Allergic Rhinitis Now Available in Japan
Benzinga's Top Initiations
Novo Nordisk's First Diabetes Pill Could Be A $10-20B Super-Blockbuster (Seeking Alpha)
Related GE
Credit Suisse Still Likes General Electric, But Removes Stock From Focus List
Electrolux Comments on Speculations of Settlement in GE Appliance Case
General Electric: Powering Ahead (Seeking Alpha)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and GE Healthcare today announced a clinical study collaboration, license and supply agreement for use of [^18F]Flutemetamol, an investigational positron emission tomography (PET) imaging agent, to support Merck's development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

Accumulation of beta amyloid in the brain is a pathological characteristic related to Alzheimer's disease. Currently, AD is diagnosed by clinical examination (i.e., medical history, physical, neurological, psychiatric and neuropsychological exams, laboratory tests and Magnetic Resonance Imaging [MRI] or Computed Tomography [CT] scan). An AD diagnosis can only be confirmed through histopathological identification of characteristic features, including beta amyloid plaques, in post-mortem brain samples.

Posted-In: News


Related Articles (GE + MRK)

View Comments and Join the Discussion!

Get Benzinga's Newsletters